Observational studyBMC cancer2026

Quadruplet daratumumab in combination with bortezomib, lenalidomide, and dexamethasone as front-line regimen improved clinical outcomes in high-risk myeloma patients in China: a multi-centered prospective real-world study.

Lili Cheng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.